Skip to Content
Search Menu

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

Data from the COAST-study was presented as Late-breaking at ESMO 2021. In this MEDtalk Roy S. Herbst, Medical Oncology, Yale Cancer Center, USA, gives his perspective of positive results for two new combination with durvalumab.
Roy S. Herbst

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
Lung cancerNSCLCWCLC23

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
WCLC23Lung cancerImmunotherapyNSCLC
Tejas Patil

Exceptional response of lorlatinib and cabozantinib combination in ROS1-rearranged NSCLC

/ Tejas Patil
NSCLC Play the Video 07:11
Timothy F. Burns

Osimertinib for the treatment of EGFR-mutant NSCLC in the adjuvant setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-world studies studies highlight NSCLC data gaps and survival differences from randomized controlled trials

/ Birgitte Bjørnhart
Lung cancerNSCLCDSKO23 Play the Video 5:04
Astrid Telhaug Karlsson

Survival rates for patients with NSCLC with brain metastases following whole brain radiotherapy

/ Astrid Telhaug Karlsson
Lung cancerNSCLCELCC23 Play the Video 3:22
Niels Reinmuth

Current aspects in early-stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
Lung cancerNSCLCELCC23 Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
Lung cancerNSCLCESMO22 Play the Video 5:14
Back to top